Maiwald acted as legal advisor to Royalty Pharma in connection with an innovative funding agreement totaling up to $2 billion with Revolution Medicines. The transaction includes up to $1.25 billion in synthe...
Continue reading
Cyprumed GmbH and Merck & Co., Inc. have entered a Non-Exclusive License and Option Agreement to develop oral formulations of peptides using Cyprumed’s drug delivery technology. MSD gains global non-exclusive rights...
Continue reading
The market analysis by Managing IP and the IP STARS ranking 2024 confirm this: The German market for intellectual property remains dynamic and highly competitive. Especially in the field of patent law, numerous law firms were able to maintain and expand their leading positio...
Continue reading
All press coverage
A European Patent Office board of appeal said in a ruling published on March 10th that Roche Diagnostics GmbH proved Verinata Health Inc.'s blueprint lacks an inventive step over an earlier international patent application setting out a similar way of testing "free-floating ...
Continue reading
We are happy to report that the oppositions filed by our client betapharm and eight other generics manufacturers against Novartis patent EP 3 351 246 were successful; the Board of Appeal of the European Patent Office revoked the Novartis patent for lack of inventive step (fi...
Continue reading
Maiwald GmbH in Munich has achieved an important victory for its client Acetate International LLC at the European Patent Office. Acetate International LLC is part of the Celanese group which has a long history of producing cellulose acetate products for commercial applicatio...
Continue reading
All press releases